You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 48 No. 7, July 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Correction
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Acquired Immunodeficiency Syndrome Cerebrospinal Fluid Findings in Patients Before and During Long-term Oral Zidovudine Therapy

Teresa A. Tartáglione, PharmD; Ann C. Collier, MD; Robert W. Coombs, MD, PhD; Kent E. Opheim, PhD; Dana K. Cummings, ARNP; S. Rae Mackay; Jacqueline Benedetti, PhD; Lawrence Corey, MD

Arch Neurol. 1991;48(7):695-699.


Abstract

• Fifty-two patients with acquired immunodeficiency syndrome were enrolled in this study to evaluate the relationship between cerebrospinal fluid (CSF) zidovudine concentrations and neurologic and human immunodeficiency virus (HIV) culture findings. Paired HIV-CSF culture and neurologic measurements were available in 30 and 45 patients, respectively. Twenty-nine patients were assessable for zidovudine CSF concentrations. Patients underwent lumbar puncture and neurologic testing before and after 8 weeks or more of oral zidovudine therapy (600 to 1500 mg/d). After 8 weeks of therapy, the frequency of HIV isolation from CSF cultures was unchanged. Significant neurologic improvement by examination was noted in 61.5% (32/52) of the patients. The median CSF zidovudine concentration among 29 patients was 0.047 mg/L (range, 0.015 to 0.198 mg/L). No correlation between CSF zidovudine concentration, cumulative dose, or HIV isolation from CSF and persistence or resolution of neurologic symptoms or signs was observed. The mechanisms by which zidovudine improves neurologic function are unclear and appear unrelated to direct clearance of virus from CSF.



Author Affiliations

From the University of Washington, Seattle. Drs Tartaglione and Collier are now with the Division of Infectious Diseases, Dr Benedetti and Mr Mackay are now with the Department of Biostatistics, and Ms Cummings is a Health Care Specialist with the Harborview Medical Center, Seattle; and Drs Coombs and Corey are now with the Department of Virology, and Dr Opheim is with the Department of Laboratory Medicine at the D536 Childrens Hospital, Seattle.


Footnotes

Accepted for publication February 27, 1991.

Reprint requests to Harborview Medical Center ZA-89, 325 Ninth Ave, Seattle, WA 98104 (Dr Tartaglione).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Zidovudine Reduces Intrathecal Immunoactivation in Patients With Early Human Immunodeficiency Virus Type 1 Infection
Elovaara et al.
Arch Neurol 1994;51:943-950.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.